The potentials of MS-based subproteomic approaches in medical science: the case of lysosomes and breast cancer.
Because of the great number of women who are diagnosed with breast cancer each year, and though this disease presents the lowest mortality rate among cancers, breast cancer remains a major public health problem. As for any cancer, the tumorigenic and metastatic processes are still hardly understood, and the biochemical markers that allow either a precise monitoring of the disease or the classification of the numerous forms of breast cancer remain too scarce. Therefore, great hopes are put on the development of high-throughput genomic and proteomic technologies. Such comprehensive techniques should help in understanding the processes and in defining steps of the disease by depicting specific genes or protein profiles. Because techniques dedicated to the current proteomic challenges are continuously improving, the probability of the discovery of new potential protein biomarkers is rapidly increasing. In addition, the identification of such markers should be eased by lowering the sample complexity; e.g., by sample fractionation, either according to specific physico-chemical properties of the proteins, or by focusing on definite subcellular compartments. In particular, proteins of the lysosomal compartment have been shown to be prone to alterations in their localization, expression, or post-translational modifications (PTMs) during the cancer process. Some of them, such as the aspartic protease cathepsin D (CatD), have even been proven as participating actively in the disease progression. The present review aims at giving an overview of the implication of the lysosome in breast cancer, and at showing how subproteomics and the constantly refining MS-based proteomic techniques may help in making breast cancer research progress, and thus, hopefully, in improving disease treatment.
Laboratoire de Chimie des Protéines, ERM-0201 Inserm, DRDC, CEA-Grenoble, 17 rue des Martyrs, 38054 Grenoble, France. agnes.journet@cea.fr
Agnès
A
Journet
Myriam
M
Ferro
D014408:Biomarkers, Tumor / Q000032:analysis* / Q000378:metabolism; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000201:enzymology*; D006801:Humans; D006867:Hydrolases / Q000032:analysis* / Q000378:metabolism; D008247:Lysosomes / Q000201:enzymology*; D013058:Mass Spectrometry / Q000379:methods*; D009363:Neoplasm Proteins / Q000032:analysis / Q000378:metabolism; D040901:Proteomics / Q000379:methods*
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D006867:Hydrolases